Literature DB >> 9794983

Hyperbaric oxygen therapy in the pediatric patient: the experience of the Israel Naval Medical Institute.

D Waisman1, A Shupak, G Weisz, Y Melamed.   

Abstract

UNLABELLED: The pediatric patient is to be found in hyperbaric facilities throughout the world, receiving hyperbaric oxygen (HBO) therapy for both life-threatening and chronic diseases.
OBJECTIVE: To review the experience accumulated at the Israel Naval Medical Institute in the treatment of pediatric patients.
DESIGN: A retrospective analysis and review of all records of patients younger than age 18 years.
RESULTS: Between 1980 and 1997, 139 pediatric patients age 2 months to 18 years (mean, 7.7 years) received HBO treatment at the Israel Naval Medical Institute. Of the children, 111 (79%) suffered from acute carbon monoxide (CO) poisoning; 13 (9.2%) were treated after crush injury, traumatic ischemia, or compartment syndrome; 4 (2.8%) had clostridial myonecrosis; 1 (0.7%) had necrotizing fasciitis; 5 (3.6%) had refractory osteomyelitis; 2 (1.4%) had suffered massive air embolism; 2 (1.4%) had purpura fulminans; and 1 (0.7%) suffered from decompression sickness. Outcome, judged by neurologic sequelae, mortality, and extent of soft tissue loss and limb amputation, was favorable in 129 patients (93%). Two patients (1.4%) died, 1 as a result of CO poisoning and the other, gas gangrene; 2 of the patients in the CO group (1.4%) remained with neurologic sequelae, and 6 patients in the acute traumatic ischemia group (4.3%) underwent limb amputation.
CONCLUSIONS: We had a favorable experience with 129 of a total 139 pediatric patients treated at our facility for the indications listed. A basic knowledge of HBO therapy is needed to refer the pediatric patient for treatment when indicated. The needs of the pediatric patient, especially the critically ill, require specific skills and equipment inside the hyperbaric chamber. Close collaboration between the pediatrician and the hyperbaric medicine physician is essential to ensure adequate care for infants and children.

Entities:  

Mesh:

Year:  1998        PMID: 9794983     DOI: 10.1542/peds.102.5.e53

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

1.  A different approach to the management of necrotizing fasciitis in neonates: hyperbaric oxygen.

Authors:  Secil Aydinoz; Senol Yildiz
Journal:  Int Wound J       Date:  2007-03       Impact factor: 3.315

2.  Effects of hyperbaric oxygen on the expression of claudins after cerebral ischemia-reperfusion in rats.

Authors:  Hong Zhao; Qianru Zhang; Yixue Xue; Xuexin Chen; Randy S Haun
Journal:  Exp Brain Res       Date:  2011-05-31       Impact factor: 1.972

3.  Meningococcal purpura fulminans in children: I. Initial orthopedic management.

Authors:  E Nectoux; A Mezel; S Raux; D Fron; M Maillet; B Herbaux
Journal:  J Child Orthop       Date:  2010-08-17       Impact factor: 1.548

4.  Hyperbaric oxygen therapy for the treatment of brain abscess in children.

Authors:  Senta Kurschel; Amir Mohia; Verena Weigl; Hans Georg Eder
Journal:  Childs Nerv Syst       Date:  2005-05-05       Impact factor: 1.475

5.  Hyperbaric oxygen treatment of superficial soft tissue lesions in children with oncologic disease.

Authors:  Eleonora Cesca; Giacomo Garetto; Emanuela Frascella; Simone Cesaro; Patrizia Dall'igna; Giovanni Cecchetto
Journal:  Pediatr Rep       Date:  2011-12-27

6.  Hyperbaric oxygen therapy in branch retinal artery occlusion in a 15-year-old boy with methylenetetrahydrofolate reductase mutation.

Authors:  Ali Riza Cenk Celebi; Sibel Kadayifcilar; Bora Eldem
Journal:  Case Rep Ophthalmol Med       Date:  2015-02-05

7.  Hyperbaric oxygen in children with cerebral palsy: A systematic review of effectiveness and safety.

Authors:  Justine Laureau; Christelle Pons; Guy Letellier; Raphaël Gross
Journal:  PLoS One       Date:  2022-10-14       Impact factor: 3.752

8.  Hyperbaric oxygen treatment for intrauterine limb ischaemia: a newborn in the chamber.

Authors:  Bengusu Mirasoglu; Hande Cetin; Sevgi Ozdemir Akgun; Samil Aktas
Journal:  Diving Hyperb Med       Date:  2021-06-30       Impact factor: 1.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.